# PeptideScanner evidence objects: Sermorelin

Every published version of the records placed with Sermorelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/sermorelin.json. Selected public evidence only; not medical advice.

- Objects: 5
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="fda-drugs-nda019863-v1"></a>

## Drugs@FDA application NDA019863

> The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019863:v1`
- Evidence domain: Regulatory
- Date in source: 1990-12-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019863/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#fda-drugs-nda019863-v1
- Content SHA-256: `10d6c2677c588683b7fabda63af96877985f43284e1b72527592b486290e04cf`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019863 ([`fda-drugs-nda019863-1990-12-28-e8b206cc80df`](#source-fda-drugs-nda019863-1990-12-28-e8b206cc80df))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients. ([`fda-drugs-nda019863-1990-12-28-e8b206cc80df`](#source-fda-drugs-nda019863-1990-12-28-e8b206cc80df))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019863 with status AP dated 1990-12-28, and names sermorelin acetate among the application record's active ingredients. ([`fda-drugs-nda019863-1990-12-28-e8b206cc80df`](#source-fda-drugs-nda019863-1990-12-28-e8b206cc80df))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019863-1990-12-28-e8b206cc80df`](#source-fda-drugs-nda019863-1990-12-28-e8b206cc80df))

### Sources

<a id="source-fda-drugs-nda019863-1990-12-28-e8b206cc80df"></a>
- **Drugs@FDA application NDA019863 · original submission status AP · 1990-12-28 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019863%22&limit=1) (`fda-drugs-nda019863-1990-12-28-e8b206cc80df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019863." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#fda-drugs-nda019863-v1 SHA-256: 10d6c2677c588683b7fabda63af96877985f43284e1b72527592b486290e04cf.

---

<a id="fda-drugs-nda020443-v1"></a>

## Drugs@FDA application NDA020443

> The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020443:v1`
- Evidence domain: Regulatory
- Date in source: 1997-09-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020443/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#fda-drugs-nda020443-v1
- Content SHA-256: `d0a71836c039819d61741cc85a966a59589fe3b111eac7e00d1e497e40292cc8`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020443 ([`fda-drugs-nda020443-1997-09-26-957ec2aa11e7`](#source-fda-drugs-nda020443-1997-09-26-957ec2aa11e7))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients. ([`fda-drugs-nda020443-1997-09-26-957ec2aa11e7`](#source-fda-drugs-nda020443-1997-09-26-957ec2aa11e7))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020443 with status AP dated 1997-09-26, and names sermorelin acetate among the application record's active ingredients. ([`fda-drugs-nda020443-1997-09-26-957ec2aa11e7`](#source-fda-drugs-nda020443-1997-09-26-957ec2aa11e7))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020443-1997-09-26-957ec2aa11e7`](#source-fda-drugs-nda020443-1997-09-26-957ec2aa11e7))

### Sources

<a id="source-fda-drugs-nda020443-1997-09-26-957ec2aa11e7"></a>
- **Drugs@FDA application NDA020443 · original submission status AP · 1997-09-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020443%22&limit=1) (`fda-drugs-nda020443-1997-09-26-957ec2aa11e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020443." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#fda-drugs-nda020443-v1 SHA-256: d0a71836c039819d61741cc85a966a59589fe3b111eac7e00d1e497e40292cc8.

---

<a id="federal-register-2013-04827-v1"></a>

## Federal Register notice 2013-04827

> The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin.

- Evidence object: `story:federal-register-2013-04827:v1`
- Evidence domain: Regulatory
- Date in source: 2013-03-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2013-04827/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#federal-register-2013-04827-v1
- Content SHA-256: `946402240d930a604a251c0d1db1b4ba11060791c5c79473f4f0b1426410914d`

### Claims and source pins

#### Headline

Federal Register notice 2013-04827 ([`federal-register-2013-04827-72d90717f32d`](#source-federal-register-2013-04827-72d90717f32d))

#### Summary

The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin. ([`federal-register-2013-04827-72d90717f32d`](#source-federal-register-2013-04827-72d90717f32d))

#### Paragraph 1

The Federal Register published notice 2013-04827, attributed to FDA and its parent HHS department, on 2013-03-04. Its official title is “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Sermorelin. ([`federal-register-2013-04827-72d90717f32d`](#source-federal-register-2013-04827-72d90717f32d))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2013-04827-72d90717f32d`](#source-federal-register-2013-04827-72d90717f32d))

### Sources

<a id="source-federal-register-2013-04827-72d90717f32d"></a>
- **Federal Register notice 2013-04827 · published 2013-03-04 · Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf) (`federal-register-2013-04827-72d90717f32d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2013-04827." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#federal-register-2013-04827-v1 SHA-256: 946402240d930a604a251c0d1db1b4ba11060791c5c79473f4f0b1426410914d.

---

<a id="pubmed-pmid-18031173-sermorelin-v1"></a>

## Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

> PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18031173-sermorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-10-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18031173-sermorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#pubmed-pmid-18031173-sermorelin-v1
- Content SHA-256: `dc855ca2be06b671f9da0b0392cf06f7b4f0820e5127400f143a355997eb43e8`

### Claims and source pins

#### Headline

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. ([`pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831`](#source-pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831))

#### Summary

PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831`](#source-pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831))

#### Paragraph 1

PubMed lists PMID 18031173 in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy as Journal Article, with publication-date metadata of 1999-08 (month precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831`](#source-pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831`](#source-pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831))

### Sources

<a id="source-pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831"></a>
- **Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. · retained source version 1:2018-10-25:current:ce9838a7f8311731f957921bfe5963757aee3486dc6fbb1272aad56e35393d3c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18031173/) (`pubmed-observation-pmid-18031173-2018-10-25-ce9838a7f831`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#pubmed-pmid-18031173-sermorelin-v1 SHA-256: dc855ca2be06b671f9da0b0392cf06f7b4f0820e5127400f143a355997eb43e8.

---

<a id="pubmed-pmid-18046908-sermorelin-v1"></a>

## Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

> PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18046908-sermorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18046908-sermorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#pubmed-pmid-18046908-sermorelin-v1
- Content SHA-256: `bf3e4428d1be4272e3e53efc83068d3850f0559aa6948ca7ca245998d7013f79`

### Claims and source pins

#### Headline

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? ([`pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3`](#source-pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3))

#### Summary

PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3`](#source-pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3))

#### Paragraph 1

PubMed lists PMID 18046908 in Clinical interventions in aging as Editorial, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug sermorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3`](#source-pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3`](#source-pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3))

### Sources

<a id="source-pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3"></a>
- **Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? · retained source version 1:2021-10-20:current:daded1ed37f3a4740b3f8e1f6ea26cf01909ca7be57ee8ec8ae8953d210611d1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18046908/) (`pubmed-observation-pmid-18046908-2021-10-20-daded1ed37f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/sermorelin.json#pubmed-pmid-18046908-sermorelin-v1 SHA-256: bf3e4428d1be4272e3e53efc83068d3850f0559aa6948ca7ca245998d7013f79.

